Anti-fog suction device during nose-route surgery for pituitary adenoma or craniopharyngioma
Tests a lens anti-fog suction device in adults having pituitary region tumor surgery.
Key facts
- Who runs it
- West China Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Anti-fog suction device-a 4 Fr multi-channel silicone catheter
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a pituitary adenoma or craniopharyngioma who are planned for surgery through the nose with an endoscope. It tests a device that keeps the camera lens from fogging.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Pituitary adenoma or craniopharyngioma of ≤ 3 cm (1.2 in) on MRI/CT, without extensive spread into the skull base. Planned elective endoscopic endonasal transsphenoidal surgery. General health ASA class I-III.
- Earlier treatment
- People whose earlier nose surgery prevents placing the device cannot join.
Main reasons for not taking part
- Severe nose deformity, polyps or earlier nose surgery that prevents placing the device
- Active nose or body-wide infection (WBC > 10 × 10⁹/L, CRP ≥ 10 mg/L), known brain infection or ongoing CSF (brain fluid) leak
- Blood clotting problems (PT > 14 s or APTT > 45 s) or blood thinners that cannot be stopped for ≥ 7 days
- Allergy to silicone or medical-grade plastics, or a planned combined approach through the skull or eye socket
- Pregnancy or breastfeeding, or a mental or cognitive disorder that prevents consent or follow-up
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 18-75 years
- Pre-operative MRI/CT diagnosis of pituitary adenoma or craniopharyngioma ≤ *3 cm without extensive skull-base invasion
- Scheduled for elective endoscopic endonasal transsphenoidal resection
- ASA physical status I-III
- Able and willing to give written informed consent and comply with follow-up
Who cannot take part
- Severe nasal anatomical deformity, polyps, or prior nasal surgery preventing device placement
- Known intracranial infection or ongoing CSF leak
- Allergy to silicone or medical-grade plastics
- Psychiatric or cognitive disorder precluding informed consent or follow-up
- Active nasal or systemic infection (WBC > 10 × 10⁹/L, CRP ≥ 10 mg/L)
- Coagulopathy (PT > 14 s or APTT > 45 s) or anticoagulation that cannot be stopped ≥ 7 days
- Planned combined transcranial or transorbital approach
- Pregnancy or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does the device reduce the total time the surgeon has to stop because the lens fogs up? * What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used?
Researchers will compare the anti-fog device to the usual "water-squirt" method to see if the device works better.
Participants will:
* Have either the device or the usual water method applied during their planned pituitary surgery * Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7 * Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery
The 2 groups in the trial
- Intervention groupTreatment being tested
A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia. The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana. Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensation. Two side ports provide continuous low-pressure (-5 cmH₂O) suction of any blood or fluid, keeping the surgical field dry. The device remains in place for the entire operation and is removed before nasal packing. No extra incisions or sutures are required.
Treatment: Anti-fog suction device-a 4 Fr multi-channel silicone catheter
- Control groupNo study treatment, for comparison
Standard care: whenever the lens fogs, the scrub nurse withdraws the endoscope and irrigates its tip with 5-10 ml of 37 °C sterile saline from a 20 ml syringe. This manoeuvre is repeated as often as necessary (average 10-15 times per case).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
- Plain-language title
- Anti-fog suction device during nose-route surgery for pituitary adenoma or craniopharyngiomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07316101, who can take part
- Record updated
- 30 June 2026